Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
about
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareCUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression.Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients - Early Results of a Phase II Trial.Tumor-associated edema in brain cancer patients: pathogenesis and management.Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma.Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.Progress in European neurology 2012-2013.Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients.
P2860
Q26851160-893B3752-B604-4EFD-87D6-8DB508A136BAQ34437996-010743A3-4C0E-44DA-BA91-3699E0BA947AQ35388346-CF6EBC0B-5C52-4DDA-9642-A74AD8513D89Q36320980-1A96815A-ACCA-4724-9CAC-C6B778AC5919Q38154959-0E84A8AA-D6C9-4F3C-945B-D8819DAD0076Q38587724-4EB65DD5-8634-4395-8F29-105036216D03Q38718044-AF141067-ED4A-479A-A461-1E7CDC16EF44Q41686732-E18E8A9A-3094-4753-BBC9-9BE938C861E3Q42282790-C68F4835-1887-4FF8-ACD7-8BC2CDD54F12Q46040914-6904BCF4-E2FE-4407-B49E-CC22537DDA5FQ47863448-D835DE6A-2CDC-4898-B870-06F3DF296B0EQ49015944-B1B71ED7-BC43-4768-83B3-B39A8FECBE3F
P2860
Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
@en
Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
@nl
type
label
Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
@en
Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
@nl
prefLabel
Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
@en
Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
@nl
P2093
P2860
P1476
Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.
@en
P2093
A F Carpentier
A-L Dubessy
P2860
P304
P356
10.1111/J.1468-1331.2012.03766.X
P577
2012-05-31T00:00:00Z